Author:
Dodd Lori E.,Korn Edward L.,Freidlin Boris,Gray Robert,Bhattacharya Suman
Subject
Applied Mathematics,General Agricultural and Biological Sciences,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,Statistics and Probability
Reference16 articles.
1. Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense;Dodd;Journal of Clinical Oncology,2008
2. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1);Eisenhauer;European Journal of Cancer,2009
3. EMEA 2008 Methodological considerations for using progression-free survival (PFS) as primary endpoint in confirmatory trials for registration http://www.emea.europa.eu/pdfs/human/ewp/2799408en.pdf
4. FDA 2007 Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071590.pdf
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献